Cardiologist receives $7M for 5-year study to boost care for heart failure patients

Larry Allen, MD, a cardiologist with the University of Colorado School of Medicine, has received $7 million in funding from the Patient-Centered Outcomes Research Institute (PCORI) to investigate the use of electronic resources among heart failure patients. The study is expected to last five years and include a total of five health systems. It could enroll as many as 2,000 patients. While $2.5 million will go to the University of Colorado, $2.5 million will go to the four other health systems: Yale New Haven Health in Connecticut, Northwestern Medicine in Illinois, University of Utah Health and Sutter Health in California. The final $2 million will help fund the actual development and structure of the study. “Heart failure is one of the most common chronic diseases in the United States, especially among older people,” Allen said in a prepared statement announcing the news. “It’s a significant problem. It’s associated with many symptoms, like shortness of breath and a lot of fatigue. It’s the most common cause of hospitalization among Medicare beneficiaries.”

American Heart Association funds cardiovascular research at MMRI

Researchers from the Masonic Medical Research Institute (MMRI) recently made presentations about their cardiovascular research projects, funded to the tune of $499,000 by the American Heart Association. From left to right are Amy Demetri, board member of American Heart Association; Khanh Ha, postdoctoral fellow at MMRI; Kelly Leogrande, wife of red cap ambassador; Ryan Leogrande, survivor and red cap ambassador; Luana Nunes Santos, postdoctoral fellow at MMRI; Maria Kontaridis, MMRI executive director; Nathan Tucker, assistant professor of biomedical research and translational medicine at MMRI; Max Majireck, associate professor of chemistry at Hamilton College; Ryan Rahman, student at Hamilton College; Frank Williams, board member at MMRI. (Photo credit: MMRI) UTICA, N.Y. — Four scientists at the Masonic Medical Research Institute (MMRI) currently have cardiovascular research projects funded by the American Heart Association totaling $499,000. “The funding provided by the American Heart Association allows MMRI to make significant strides towards finding ways to not only prevent, but to treat heart disease,” MMRI Executive Director Maria Kontaridis said in a press release. “All of us at MMRI are extremely grateful for the American Heart Association’s generous support.” The researchers presented brief overviews of their projects on Nov. 28 to board members from MMRI and the American Heart Association as well as the public. Kontaridis is researching whether there is a connection between congenital heart defects and autism. She also serves as the vice chair of the American Heart Association’s Basic Cardiovascular Sciences Council Leadership Committee. Kontaridis received the Transformational Project Award for $73,432 for her collaborative research project that researches the impact of damaged proteins on the structure and electrical signaling of the heart. Luana Nunes Santos received a diversity supplement award of $133,480 for two years to work with Kontaridis on the autism and congenital heart-defects project. The grant, which has concluded, promotes diversity and inclusion in the sciences. Khanh Ha, along with Hamilton College associate chemistry professor Max Majireck, has a grant for a project that aims to identify a new type of drug-delivery system that targets the plaques found in atherosclerosis. Nathan Tucker was awarded a $200,000 Innovative Project Award for two years that allows him and his team to focus on the strong impact genetics have on the risk of severe cardiovascular disease. Survivor Ryan Leogrande, who served as a Red Cap Ambassador to America’s Greatest Heart Run & Walk in 2022, talked about research and what it means to people living with heart disease. “After watching myself flatline, I made a number of life changes, including better diet and more exercise,” he said. “Like the great projects the American Heart Association is funding at Masonic Medical Research Institute, those changes are part of the research of the American Heart Association. My three sons, my wife and I support the American Heart Association so that other dads can be around to watch their children grow up.” “Since 1949, the American Heart Association has invested more than $5.7 billion in research,” said Amy DeMetri, executive VP of First Source Federal Credit Union and member of the board of directors of the American Heart Association in the Mohawk Valley. “We are currently funding 1,700 projects for a total of $479 million worldwide. We are very proud to be funding $499,000 right here at MMRI. It’s exciting that so much of the money we raise remains right here in the Mohawk Valley, stays in the Mohawk Valley. I know the work done here will have a positive impact on many lives in many places, starting right here.” MMRI conducts research on the causes of cardiovascular, neurocognitive, and autoimmune diseases to identify treatments and cures.

4 consejos para mejorar la salud cardiovascular y aumentar la esperanza de vida

Cuidar la salud puede ser un asunto complejo, sin embargo, puede aumentar la esperanza de vida. Y, por fortuna, hay una serie de consejos y hábitos que pueden ayudarte a mantenerte en forma. De hecho, en un estudio sobre riesgos cardiovasculares (realizado en 6,500 adultos), la Asociación Americana del Corazón destaca que una buena salud cardiovascular puede reducir las enfermedades relacionadas con la edad. Además, de acuerdo con el epidemiólogo Nour Makarem, el estudio reveló que “una mejor salud cardiovascular se asocia a un envejecimiento biológico más lento […]. También encontramos una asociación dosis-dependiente: cuanto mayor es el nivel de salud cardiovascular, más lento es el envejecimiento biológico”. Se trata de una excelente noticia que podría ayudarnos a mantenernos jóvenes durante más tiempo. Pero el estudio va aún más lejos, pues anuncia que con cierta rutina se pueden ganar 6 años en la lucha antiedad, a diferencia de las personas que descuidan su salud y que aparentan más edad. Entonces, ¿cuáles son los consejos para aumentar la esperanza de vida? He aquí la respuesta. 1. Mantente activo Según el estudio, los adultos deberían dedicar al menos 30 minutos a hacer deporte moderado o 75 minutos de deporte de alta intensidad durante la semana, mientras que los niños deben hacer una actividad física al menos una hora al día. Hacer ejercicio te dotará de muchos beneficios. South_agency Pero, ¿cómo puedes ser más activo? Para mejorar tu salud cardiovascular, es aconsejable fortalecer los músculos, lo que puede implicar fortalecerlos al menos dos veces por semana cuando hagas deporte. También es buena idea evitar estar demasiado tiempo sentado y mantenerse en movimiento a lo largo del día. Por fortuna, los que pensaban que había que dar al menos 10,000 pasos al día deben saber que la cifra es inferior. 2. Dormir bien Como siempre decimos, dormir es la clave de una buena salud. La OMS recomienda que los adultos duerman entre 7 y 9 horas por noche para mejorar su salud mental y física. Dormir lo suficiente favorece enormemente la cicatrización, mejora la función cerebral y reduce el riesgo de enfermedades crónicas. ¿Cómo puedes dormir mejor? Dormir delante de la tele es muy malo para el descanso, y aún peor si cargas el celular durante la noche. Los teléfonos deberían estar prohibidos cuando te acuestas, ya que su luz azul altera tu reloj biológico y reduce la producción de melatonina, la hormona del sueño. Si sigues teniendo problemas para dormir, el ejército estadounidense ha desarrollado una técnica que permite conciliar el sueño en únicamente dos minutos. 3. Come mejor La alimentación desempeña un papel esencial en la buena salud. Comer menos sal, así como más fruta y verdura te ayudará a mantener el colesterol bajo control y a limitar el riesgo de accidentes cardiovasculares.

Are You Getting Enough Vitamin D to Protect Your Heart? New Research Says Maybe Not

Current vitamin D dosage recommendations may not be high enough, according to new research. Two new studies from Intermountain Health, presented at the American Heart Association’s 2023 Scientific Sessions, focused on vitamin D’s effects on heart disease and stroke. In doing so, they found that the current dosage recommendations for the micronutrient may be too low. Insufficient amounts of vitamin D can lead to serious health consequences. “We have previously evaluated vitamin D in observational studies and found insufficient levels to be associated with adverse cardiovascular outcomes,” lead study author Heidi May, PhD, told Health. May explained that other observational studies have reported similar findings, so the research team wanted to evaluate the association in a randomized clinical trial. The current daily recommendation for vitamin D is 600 International Units (IU) for adults aged 19–70, and 800 IU for adults 71 and older. Here’s why the current vitamin D dosage recommendation may not be enough, how too little vitamin D can negatively impact your cardiovascular health, and how to ensure you’re getting enough vitamin D. Getty Images / Istockexstock There are a few ways someone can take in vitamin D. Known as “the sunshine vitamin,” solar rays are the primary source of vitamin D. The nutrient is also found in some foods like fortified milk, orange juice, fatty fish, and beef liver. Enough vitamin D can provide multiple health benefits, including: Reduced inflammation Protection against osteoporosis Neuromuscular function Immune function One of the lesser-known effects of vitamin D is its positive impact on the cardiovascular system. This is likely due to its anti-inflammatory action. “Vitamin D supports heart health by regulating blood pressure, reducing inflammation, and improving function of blood vessels, promoting better blood flow,” Veronica Rouse, RD, CDE, of The Heart Dietitian, told Health. According to May, multiple previous studies have established these benefits. “Many risk factors for heart disease have been shown to be affected by vitamin D, such as high blood pressure, diabetes, and being overweight,” she said. Knowing that vitamin D could impact heart health, the research team set out to determine whether current dosing recommendations are helping people achieve optimal levels. In the first of the two studies, 632 patients were enrolled in a randomized clinical trial and divided into two groups. One group received targeted, personalized vitamin D treatment, while the other simply received a general recommendation to talk to their doctor about vitamin D supplementation. Those in the targeted treatment group received vitamin D supplements as needed to help them achieve blood levels of over 40 nanograms per milliliter (ng/ml), identified as a baseline optimal level for cardiovascular disease prevention. Those in the doctor discussion group received no specific amount of supplementation. Remarkably, 86.5% of subjects in the as-needed dosing group required more than 2,000 IU of daily vitamin D to achieve a 40 ng/ml blood level, and 14.6% required over 10,000 IU daily. Reaching these levels wasn’t a quick process. Less than 65% of subjects got to the 40 ng/ml mark in three months, and 25% needed at least six months to get there. To measure the impact of these findings on heart health, the research team conducted an additional analysis. This time, they identified subjects who had a cardiovascular event within 30 days of enrollment in the study. In these people, baseline vitamin D levels were a median of 25 ng/ml, significantly below the optimal 40 ng/ml level. May explained that her main takeaway from these studies is that ideal vitamin D intake (especially for heart health) may need to be targeted to individuals, rather than based on a blanket daily recommendation. “Prior vitamin D supplementation studies gave everyone the same dose of vitamin D, regardless of their blood level,” she said. “This study will be the first to show whether it is important for a patient to obtain a certain blood level of vitamin D to reduce their risk of having an adverse cardiovascular event.” Since people’s vitamin D needs can vary, it might be tricky to understand how much you personally need, and whether or not you’re getting that amount from food and sunshine alone. Having your levels tested regularly can give you a sense of whether your intake is sufficient. “Testing vitamin D levels in the blood and speaking with a healthcare provider will be the best way to determine how much vitamin D you should take, especially when considering higher doses,” Rouse said. Certain health conditions may also increase your needs. People with difficulty absorbing nutrients due to inflammatory bowel disease, celiac disease, cystic fibrosis, or bariatric surgery may need to supplement with extra vitamin D. If you’d like to add a supplement, talk to your doctor about how many IUs are too many. Higher doses than the recommended 600-800 IU per day can be safe—but only up to a point. According to the National Institutes of Health, ingesting too much vitamin D could result in adverse side effects like nausea, vomiting, poor appetite, dehydration, and kidney stones. Besides adding a supplement to your routine, you can always boost your vitamin D levels with dietary choices. “To achieve optimal Vitamin D levels, dietary sources like fatty fish, egg yolks, and fortified foods are key,” Rouse said. Both vitamin D-fortified milk and orange juice, for example, contain just under 100 IU per cup. Or, for an even greater boost, try cod liver oil; it contains 1,360 IU of vitamin D per tablespoon. Spending time in the sun is another simple way to increase your body’s natural production of this vitamin. Try an outdoor walk around midday when the sun’s UVB rays are the most intense. Expose more of your skin to allow for greater absorption. With the right combination of time in the sun, high-vitamin D foods, and supplementation, you’ll optimize your levels for heart health and other benefits.

Avidity Biosciences inks drug discovery deal worth up to $2.3B with industry heavyweight

“This strategic collaboration solidifies our commitment in cardiology as we continue to advance our own research and development programs in cardiac indications,” Sarah Boyce, president and chief executive officer at Avidity, said in a statement. “We look forward to broadening the utility of the AOC platform to address debilitating diseases previously unreachable with existing RNA therapies.” “This collaboration with Avidity represents an important part of our continued investment in innovative therapeutic approaches that have the potential to provide transformative outcomes to patients living with serious cardiovascular conditions,” added Francisco Ramírez-Valle, MD, PhD, senior vice president and head of the Immunology & Cardiovascular Thematic Research Center at Bristol Myers Squibb. “Aligned with our focus on causal human biology and efforts to successfully match therapeutic modalities to disease mechanism, our R&D organization will continue to leverage technologies like Avidity’s AOC platform to identify meaningful targets and develop new medicines for patients in need.”

Robotic-assisted CABG reduces healthcare costs, primarily thanks to shorter hospital stays

Dokollari et al. provided a quick explanation of how these robotic-assisted surgeries worked. “In short, robotic-assisted CABG includes the robotic harvest of the left internal thoracic artery (LITA) followed by its direct anastomosis to the left anterior descending artery with a small anterior thoracotomy (4 cm) at the site of the camera port,” they explained. “The robotic procedures start with the introduction of three ports in the midclavicular/anterior axillary line, in second, fourth and sixth intercostal space. The 3D view offered by the robotic platform enhances the visualization of the LITA, lowering the risk of vessel injury and enabling the surgeon to harvest a longer LITA graft by means of skeletonization. By extending the camera port size to a 4-cm skin incision, the surgeon can perform an off-pump coronary anastomosis using a composite off-pump retractor and off-pump technique to complete the anastomosis.” Beginning with clinical outcomes, the authors reported that traditional CABG patients were associated with spending twice as much time in the ICU and spending two more full days at the hospital than robotic-assisted CABG patients. Traditional CABG patients were also linked to higher rates of blood product transfusions and new-onset atrial fibrillation (AFib). On the other hand, all-cause hospital readmissions in the first 30 days following treatment were nearly three times as common among robotic-assisted CABG patients (9%) than traditional CABG patients (3.4%). Patients were followed for a median follow-up period of 1.5 years. Rates of all-cause mortality, stroke, myocardial infarction and repeat intervention were all comparable between the two treatment techniques. Moving on to the costs of each technique, Dokollari and colleagues found that the total costs linked to robotic-assisted CABG were approximately $5 million, or $18,726 per patient, and the total costs linked to traditional CABG were approximately $9.5 million, or $35,580 per patient. Even when adding in the total cost of the robotic surgical system—approximately $1.2 million—the indirect and direct costs were significantly lower among patients treated with robotic-assisted CABG. Length of stay, the researchers noted, appeared to make the most significant impact on total costs by far. This highlights the importance of tracking post-operative outcomes such as new-onset AFib, which can cause patients to spend a longer time in the hospital. The team also emphasized that it may take time for surgeons to feel comfortable using these robotic surgical systems. “A surgeon on the early learning curve of the procedure is likely to incur higher initial operative costs than one who has performed 50-100 cases,” they wrote. Click here for the full study.

Longview cardiovascular surgeon added to Beating Heart Hall of Fame

LONGVIEW, Texas (KETK) – A Longview hospital announced on Tuesday that one of their cardiovascular surgeons was named to the Diamond Level of the Beating Heart Hall of Fame. Dr. David Jayakar with the cardiovascular team at the Heart and Vascular Institute at Longview Regional Medical is the 47th person in the U.S., and first in East Texas, to achieve this level having completed more than 1,100 off-pump coronary artery bypass procedures, according to the hospital. East Texas Women: Pianist Louverl Griffin won’t let her love for God fall flat “I am truly honored to receive the Heartbeat Hall of Fame Award,” Jayakar said. “Beating heart surgeries have the potential to transform the lives of patients in need of cardiac intervention. I am grateful for the opportunity to offer beating heart surgery here in East Texas.” Left to right: Chad Campbell, CHS Region 4 President, Dr. David Jayakar, Steve Gordon, CEO Longview Regional. Photo courtesy of Longview Regional. The hospital said that beating heart surgery, or off-pump surgery, is an innovative approach that reduces risk by performing intricate cardiac procedures without stopping the heart or putting the patient on a heart-lung machine. “Dr. Jayakar has been a pioneer in East Texas in the field of off-pump cardiac surgery and his dedication to perfecting this technique and along with his commitment to his patient’s well-being and quality outcomes have earned him this prestigious award,” the hospital said in a statement. “The ‘Hall of Fame’ is a testament to Dr. Jayakar’s exemplary skills and tireless efforts in advancing the field of cardiac surgery in Longview.”

Ventric Health Named Best Digital/Mobile Health Solution in the Fierce Healthcare Innovation Awards 2023 for Its Vivio System™

Device aiding noninvasive heart failure diagnosis chosen for the prestigious award based on its effectiveness, technical innovation, financial impact, and other judgment criteria PASADENA, Calif., Nov. 29, 2023 /PRNewswire/ — Ventric Health, a healthcare technology company and medical device provider focused on cardiovascular health, today announced the Vivio System™ was named Best Digital/Mobile Health Solution in the prestigious Fierce Healthcare Innovation Awards 2023. Vivio®, a mobile, tech-enabled device aiding clinicians in heart failure diagnosis, is simple to use but sophisticated in function. Vivio uses advanced algorithms to detect elevated left ventricular end-diastolic pressure (LVEDP) quickly and non-invasively. “This award underscores that healthcare innovation can transform outcomes and drive efficiency, positively impacting both patient well-being and the economics of care,” said Sean Brady, co-founder and CEO at Ventric Health. “We designed Vivio to democratize healthcare and overcome traditional barriers to access. The device is portable, fits in a backpack, and offers rapid detection of elevated LVEDP—the gold standard in heart failure—in under five minutes in any care setting. Vivio represents a unique quantum step forward in enabling the diagnosis of this costly and deadly condition within Medicare populations.” Up to 50% of heart failure patients are undiagnosed, and diagnosis can lag up to 30 months following the initial onset of symptoms. Early diagnosis is crucial for treating and managing heart failure in the most vulnerable populations, those that are age 65 or older. Because of the lag in diagnosis, clinical research has shown 65% of Medicare patients are first diagnosed with heart failure in the ER or inpatient setting, and this number increases to 75% for patients with lower socioeconomic status. The economic impact of heart failure is profound –– making early detection and diagnosis even more critical. Heart failure is predicted to account for $70 billion of U.S. healthcare expenditures by 2030. The Vivio System received FDA 510(k) clearance in October 2023. The Fierce Healthcare Innovation Awards program showcases outstanding innovation, driving improvements and transforming the industry. Judges scored all the entries on the ability of the applicant to demonstrate the following: effectiveness, technical innovation, competitive advantage, financial impact, and true innovation. The winners were announced on Nov. 29 in the Innovation Report, which features spotlights and interviews of all category winners. To learn more about Vivio and how Ventric Health drives the tech-enabled revolution in detecting heart failure, visit the Vivio resource page. About VentricVentric Health is a healthcare technology company and medical device provider transforming clinical interventions in cardiovascular health. We are the first and only company to enable non-invasive diagnosis of heart failure within a clinical and home health care environment, which has reshaped the diagnostic pathway for at-risk populations and set a new standard for the industry. Through our academic origins, we were able to capture unprecedented scientific data on the human heart and, today, are using that insight to develop a suite of innovations that reduces the impact of cardiovascular disease, enabling value-based care organizations and healthcare teams to lower costs and improve patient lives. To learn more visit https://www.ventrichealth.com/. Media ContactJanet MordecaiAmendola Communications for Ventric Health[email protected] SOURCE Ventric Health

Coronary Heart Disease, Especially With Early Onset, Linked to Dementia

WEDNESDAY, Nov. 29, 2023 (HealthDay News) — Coronary heart disease (CHD) is associated with increased risks for developing all-cause dementia, Alzheimer disease, and vascular dementia, with higher risks for younger age at CHD onset, according to a study published online Nov. 29 in the Journal of the American Heart Association. Jie Liang, from the Chinese Academy of Medical Sciences & Peking Union Medical College in Beijing, and colleagues examined the association of age at onset of CHD with incident dementia using data from the U.K. Biobank. Data were included for 432,667 adults, of whom 11.7 percent had CHD. The researchers found that participants with CHD had higher risks for developing all-cause dementia, Alzheimer disease, and vascular dementia compared with participants without CHD. Younger age at onset of CHD was associated with increased risks for all-cause dementia, Alzheimer disease, and vascular dementia (hazard ratios, 1.25, 1.29, and 1.22, respectively, per 10-year decrease). After propensity score matching, the risks for all-cause dementia, Alzheimer disease, and vascular dementia were significantly higher for patients with CHD than matched controls among all onset age groups, with the hazard ratios increasing gradually with decreasing age at onset. “The present findings have important public health implications as they contribute to ascertaining vulnerable populations with dementia by revealing that adults diagnosed with CHD at younger ages, especially before midlife (aged <45 years), might be the most vulnerable to future dementia," the authors write. Abstract/Full Text

2022-2023 Influenza Season Classified as High Severity by CDC

For children and adolescents aged younger than 18 years, the 2022-2023 influenza season was classified as a “high severity” season compared to previous data from the Centers for Disease Control and Prevention (CDC), the agency noted in a Morbidity and Mortality Weekly Report.1 The influenza season for 2022-2023 began in October, earlier than most previous seasons, returning to pre-COVID-19 levels. In addition to high pediatric influenza hospitalization rates, co-circulation occurred with SARS-CoV-2 and respiratory syncytial virus (RSV), sometimes referred to as the “triple-demic.” The CDC, using 3 indicators, classifies each influenza season’s severity. The indicators are the percentage of all outpatient visits with influenza-like illness (ILI), rates of laboratory-confirmed influenza hospitalization, and the percentage of all deaths because of influenza. ILI was defined as fever plus cough or sore throat and was obtained from the US Outpatient Influenza-like Illness Surveillance Network (ILINet). The Influenza Hospitalization Surveillance Network (FluSurv-NET) estimated the laboratory-confirmed hospitalization rates. Percentage of all deaths because of influenza was calculated from the National Vital Statistics System death registry. In each severity indicator, 50th, 90th, and 98th percentile intensity thresholds (Its) are, “calculated from a distribution based on the geometric mean of peak weekly values in previous seasons,” the report stated. The seasonal severity of influenza was classified as “low” if at least 2 of 3 indicators peak below IT50. Moderate, high, or very high was the classification if at least 2 of 3 indicators peaked above IT50, IT90, or IT98, respectively. The preliminary data in the CDC report, as of September 21, 2023, classified the 2022-2023 influenza season as high severity. The weekly percentage of outpatient visits for ILI, influenza-associated hospitalization rate, and percentage of deaths because of influenza all peaked between IT90 and IT98, respectively. In children aged younger than 5 years, estimated influenza-associated medical visits, hospitalization, and deaths were higher than children and adolescents aged 5 to 17 years. In the 5-to-17-year age group, influenza medical visit and hospitalization rates were higher during 2022-2023 than any other season since 2016-2017. Those younger than 5 years of age had the second highest rates of influenza-associated medical visits and hospitalization in 2022 to 2023, since 2016 to 2017. There were 11,443 medical visits per 100,000 and 119 hospitalizations per 100,000 in this age indication. Compared to previous seasons, influenza-associated deaths were low and consistent with 1.2 deaths per 100,000 children aged younger than 5 years, and 0.5 deaths per 100,000 children and adolescents aged 5 to 17 years. FluSurv-NET identified 2762 influenza-associated hospitalizations for those aged younger than 18 years from October 1, 2022, to April 30, 2023. The median age of these children was 5 years and 57.4% were male (IQR = 2-9 years). Of these individuals, 50.5% had an underlying condition, which was similar to recent influenza seasons. Asthma, neurologic disorders, and obesity were the most common underlying conditions. Most individuals were infected with influenza A (95.4%). Of this group, 80.2% were subtyped A(H3N2) and 19.6% were A(H1N1)pdm09. Over half of the 2022-2023 season’s total pediatric hospitalizations (57.1%) occurred during October and November 2022. Of those hospitalized, 18.3% received an influenza vaccine, dropping from 35.8%-41.8% in 2016-2017 through 2021-2022. The 2022-2023 influenza season was the fourth highest severity season among children and adolescents since the 2009 influenza A(H1N1) pandemic, according to the CDC. Health care systems, in particular those that had co-circulating SARS-CoV-2 and RSV, were strained because of the high incidence of influenza. Estimated by the National Immunization Survey at the peak influenza-associated hospitalization rates during the week ending November 26, 2022, 41.9% of children and teenagers aged 6 months to 17 years received the annual influenza vaccine. The report highlights the “importance of children and adolescents receiving a seasonal influenza vaccination, ideally by the end of October and prompt influenza antiviral treatment for those who are hospitalized.” The federal agency recommends all persons aged 6 months or older to receive the annual seasonal influenza vaccine. This article originally appeared in Contemporary Pediatrics. Reference 1. White EB, O’Halloran A, Sundaresan D, et al. High influenza incidence and disease severity among children and adolescents aged <18 years – United States, 2022-23 Season. MMWR Morb Mortal Wkly Rep. 2023;72(41):1108-1114. doi:10.15585/mmwr.mm7241a2